THOR - Synthorx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Synthorx, Inc.

11099 North Torrey Pines Road
Suite 190
La Jolla, CA 92037
United States
858-750-4700
http://www.synthorx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Dr. Laura K. ShawverCEO, Pres & Director606.48kN/A1958
Dr. Floyd E. RomesbergScientific Founder & Director2.68kN/A1966
Dr. Marcos Milla Ph.D.Chief Scientific Officer457.71kN/A1963
Dr. Joseph LevequeChief Medical Officer448.76kN/A1961
Terry L. ButtonVP & DirectorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

Corporate Governance

Synthorx, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.